Jump to content
Powered by
  • BIOPRO BW
  • Healthcare industry
  • Bioeconomy

Healthcare industry

Main navigation

  • Start page
  • Healthcare industry BW

    Healthcare industry BW

    Close
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles

    Articles

    Close
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events

    Events

    Close
  • Databases

    Databases

    Close
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services

    BIOPRO services

    Close
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • de
  • en
Show menu

You are here:

  1. Home
  2. Search
Show:Results per page
  • 25Show results
  • 50Show results
  • 75Show results

Search Results

  • Press release - 16/11/2021

    Cystic fibrosis & COPD: Mucus reprograms immune cells and promotes airway inflammation

    Scientists of the Translational Lung Research Center Heidelberg (TLRC) and the German Cancer Research Center (DKFZ) have discovered a new link between excessive airway mucus and chronic airway inflammation that is characteristic of cystic fibrosis and chronic obstructive pulmonary disease (COPD). The researchers showed that mucus in the airways reprograms certain cells of the immune system.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/cystic-fibrosis-copd-mucus-reprograms-immune-cells-and-promotes-airway-inflammation
  • Press release - 20/10/2020

    EIB backs Atriva Therapeutics with €24 million for the development of a potential COVID-19 treatment

    The European Investment Bank (EIB) and Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, concluded a €24 million financing agreement today to facilitate the company’s development and clinical testing of a novel therapy treating severe respiratory infections with RNA viruses. RNA viruses cause diseases such as influenza, SARS and COVID-19.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/eib-backs-atriva-therapeutics-eur24-million-development-potential-covid-19-treatment
  • Press release - 15/10/2020

    Common Vulnerabilities of Coronaviruses

    International study in which Freiburg scientists are participating maps molecular targets for possible therapy for MERS, SARS-CoV1, and SARS-CoV2.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/common-vulnerabilities-coronaviruses
  • Freudenberg Filtration Technologies - 01/10/2020 Kfz-Innenraumfilter von Freudenberg Filtration Technologies scheiden zunächst Partikel und einen Großteil viraler Areosole ab und inaktivieren diese in ihrer letzten, mit Fruchtextrakten imprägnierten bio-funktionalen Schicht

    Coronavirus thwarted: with filters against aerosol spread

    Filter technology can effectively remove microorganisms such as the new coronavirus from aerosols. A team of experts at Freudenberg Filtration Technologies develops and produces filtration solutions that effectively reduce the spread of viruses in cars, industrial plants and public buildings. The company’s filter technology for reducing the viral load is a reliable method for enabling people to stay in closed rooms with a high density of people.

    https://www.gesundheitsindustrie-bw.de/en/article/news/coronavirus-thwarted-filters-against-aerosol-spread
  • Press release - 11/08/2020

    Atriva announces closing of € 8.6 million ($ 10.2 million) oversubscribed convertible loan

    Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral therapies, today announced the closing of a € 8.6 million ($ 10.2 million) convertible loan led by Meneldor B.V. and High-Tech Gründerfonds (HTGF), and joined by existing shareholders and new German and international investors.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-announces-closing-eur-86-million-102-million-oversubscribed-convertible-loan
  • Press release - 17/04/2020

    CoroNotes: New app supports medical studies on COVID-19

    Scientists from the Tübingen Competence Center for Machine Learning and physicians from the University Hospital of Tübingen have developed an app that uses anonymous health data to contribute to a better understanding of the novel coronavirus.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/coronotes-neue-app-unterstuetzt-medizinische-studien-zu-covid-19
  • Prime Vector Technologies GmbH - 09/04/2020 Kleineres_Original_fuer_Kachel_Corona_AdobeStock_318040586_Kopie.jpg

    A modular brick system for developing a COVID-19 vaccine

    Prime Vector Technologies GmbH (PVT), a start-up company based in Tübingen in southern Germany, uses a modular brick system to develop vaccines against cancer and infectious diseases. The PVT team is currently working flat out to develop a COVID-19 vaccine.

    https://www.gesundheitsindustrie-bw.de/en/article/news/mit-einem-impfstoffbaukasten-gegen-covid-19
  • Press release - 08/04/2020

    New Alliance in the Fight Against Coronavirus and COVID-19

    Scientists from Heidelberg and Mannheim launch research and development task force

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/allianz-im-kampf-gegen-coronavirus-und-covid-19
  • Novel coronavirus outbreak - a status report on recent developments - 04/03/2020 Coronavirus, Modell

    Waiting for a SARS-CoV-2 vaccine

    Researchers around the world are working frantically on the development of a vaccine against the new coronavirus. A project by the Tübingen-based biotechnology company CureVac, funded by the Coalition for Epidemic Preparedness Innovations (CEPI), uses the company’s technology platform for mRNA-based vaccines to accelerate vaccine development, thus contributing to the future prevention of the disease.

    https://www.gesundheitsindustrie-bw.de/en/article/news/Waiting-for-a-SARS-CoV-2-vaccine
  • 02.05.2017

    World Asthma Day

    Asthma is the most common chronic disease in children. One in ten children suffer from bronchial restriction and produce elevated amounts of lung mucus. On 02.05.2017 is "World Asthma Day" – the BIOPRO provides information about this topic.

    https://www.gesundheitsindustrie-bw.de/en/article/news/world-asthma-day
  • Press release - 04/11/2016

    Atriva Therapeutics Announces Upcoming US Patent Issuance for MEK Treatment against Viral Diseases

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/atriva-therapeutics-announces-upcoming-us-patent-issuance-for-mek-treatment-against-viral-diseases
  • Article - 15/09/2014 Photo of Dr. Michael Kormann.

    Gene therapies for pulmonary disease are close to final development

    Gene therapy currently offers the only chance of curing genetic diseases such as cystic fibrosis and beta thalassaemia. Gene therapy is the replacement or correction of a mutated gene with DNA that encodes a functional gene. Intensive research has been going on in this field for many years however only a handful gene therapies are available at this point in time. Dr. Michael Kormann junior professor at the Childrens Hospital at the University of…

    https://www.gesundheitsindustrie-bw.de/en/article/news/gene-therapies-for-pulmonary-disease-are-close-to-final-development
  • Article - 30/06/2014 21541_de.jpg

    The German National Cohort: collecting data for a healthier future

    A large-scale long-term cohort study will be carried out to explain the causes of widespread diseases, in particular cancer, coronary heart disease, stroke and diabetes, and to identify the risk factors that lead to or favour the development of a certain disease. The principal objective of the German National Cohort (GNC) is to create the conditions that enable the development of new strategies for the prevention, risk assessment and early…

    https://www.gesundheitsindustrie-bw.de/en/article/news/the-german-national-cohort-collecting-data-for-a-healthier-future
  • Article - 14/01/2013 19037_de.jpg

    Boehringer takes a deep breath: a look into the company’s respiratory R&D pipeline

    At its 3rd International Research & Development (R&D) press conference, Boehringer Ingelheim gave journalists insights into its R&D pipeline. Around 200 scientists at the company’s site in Biberach are investigating new treatment options for patients with COPD (chronic obstructive pulmonary disease), asthma, idiopathic lung fibrosis, lung cancer and other respiratory diseases. In addition, the researchers are also focusing on the…

    https://www.gesundheitsindustrie-bw.de/en/article/news/boehringer-takes-a-deep-breath-a-look-into-the-company-s-respiratory-r-d-pipeline
  • Press release - 24/08/2011 You can see a computer-based model of the nasal aera of a human with a ruptured nasal cartilage. Dots demonstrate the airflow while breathing out. Different sorts of velocities were measured.

    KIT Researcher Win the Mimics Innovation Awards 2011 in the Category “Innovations in Computer Aided Engineering”

    The contribution “A Preprocessing Approach for Innovative Patient-Specific Intranasal Flow Simulations” of Krause (EMCL), Gengenbach (EMCL), Mayer (SCC), Zimny (EMCL) and Heuveline (Head of EMCL) has won the Mimics Innovation Awards 2011 in the category 2 “Innovations in computer aided engineering” which is associated with a prize of 5,000 Euro.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/kit-researcher-win-the-mimics-innovation-awards-2011-in-the-category-innovations-in-computer-aided-e
  • Article - 18/03/2011 The photo shows Dr. Thomas Bethke, Medical Director at Nycomed Germany

    Allergen research – present and future

    An allergy is a hypersensitivity disorder of the immune system. It is an exaggerated immune reaction to external stimuli such as pollen and is associated with symptoms that range in degree from uncomfortable (hay fever, asthma) to life-threatening (anaphylactic shock). Dr. Thomas Bethke, Medical Director of Nycomed Germany, explains in the following interview how a drug manufacturer approaches the research and development of anti-allergy…

    https://www.gesundheitsindustrie-bw.de/en/article/news/allergen-research-present-and-future
  • Press release - 11/09/2010 Prof. Dr. Christof Hauck and one of his colleagues in front of a computer.

    What’s new from bacteria’s box of tricks?

    Cell biologists at the University of Konstanz have discovered how specialised bacteria colonise human mucosal surfaces. Prof. Dr. Christof Haucks team is mainly interested in a mechanism known as exfoliation i.e. the shedding of epithelial cells which certain bacteria suppress in order to be able to effectively colonise mucosal surfaces.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/what-s-new-from-bacteria-s-box-of-tricks
  • Press release - 09/09/2010 10084_de.jpg

    Global market launch of Daxas® kicks off in Germany

    Stefan Brinkmann, Managing Director of Nycomed GmbH, kicked off the German market launch of Daxas® (Roflumilast) in Oranienburg today, making Germany the first country to market the medicine. Daxas® is a proprietary selective phosphodiesterase 4 (PDE4) enzyme inhibitor that was developed by Nycomed to treat the progressive, life-threatening lung disease COPD.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/global-market-launch-of-daxas-kicks-off-in-germany
  • Press release - 07/06/2010

    Addition of renowned experts to Medical Advisory Board and achievement of international quality standards generate added optimism

    With a € 1.5 Mio Second Closing, Curetis has now increased its Series A financing round to € 20 Mio. This additional financing will enable Curetis to complete the development of its innovative diagnostic products through to market entry. Quality Certification for its diagnostic product development represents an additional milestone in Curetis' commercial strategy. At the same time, Curetis has added internationally recognized expertise in…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/addition-of-renowned-experts-to-medical-advisory-board-and-achievement-of-international-quality-stan
  • Press release - 29/04/2010 10084_de.jpg

    Nycomed and Merck & Co., Inc., announce commercialization agreements for Daxas® in Europe and Canada

    Nycomed and Merck Co. Inc. based in Whitehouse Station New Jersey and known as MSD outside the USA and Canada announced that they have entered into a co-promotion agreement for Canada and certain European countries for the commercialization of Daxas roflumilast an investigational once-daily tablet for patients with chronic obstructive pulmonary disease COPD.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-and-merck-co-inc-announce-commercialization-agreements-for-daxas-in-europe-and-canada
  • Article - 18/03/2010 Restructering processes of epithelial cells occuring as the result of respiratory diseases. Model.<br />

    Boehringer Ingelheim researchers to focus on inflammation

    Boehringer Ingelheim is hoping to find ways to use anti-inflammatory mechanisms of action to improve the treatment of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and asthma. Clinical studies will show what kind of improvements patients can expect from the substances, which are currently at different stages of development. Drugs to widen the bronchia, marketed by Boehringer Ingelheim, will in the medium term become…

    https://www.gesundheitsindustrie-bw.de/en/article/news/boehringer-ingelheim-researchers-to-focus-on-inflammation
  • Article - 22/02/2010 10746_de.jpg

    Immune system discovers mould fungi through surface structures

    Mould fungus spores which are found in air aerosols are constantly being taken up in the air we inhale. As a rule this poses no danger to healthy people. However depending on the quantity of spores inhaled and the duration of exposure mould fungi could possibly lead or contribute to lung diseases and allergies. Dr. Mardas Daneshian and his team at the University of Constance are focusing on the immunostimulatory capacity of fungal spores. The…

    https://www.gesundheitsindustrie-bw.de/en/article/news/immune-system-discovers-mould-fungi-through-surface-structures
  • Dossier - 22/02/2010 10749_de.jpg

    Respiratory disease - congestion in the respiratory system

    Lung diseases are by far the most frequent cause of death worldwide. Every year three million people die from chronic obstructive pulmonary diseases 2.3 million die from lung cancer and 1.5 die from tuberculosis WHO World Health Organisation. There is no improvement in sight and experts believe that the number of deaths will continue to rise particularly in the case of chronic obstructive pulmonary diseases COPD lung cancer and tuberculosis TB.…

    https://www.gesundheitsindustrie-bw.de/en/article/dossier/respiratory-disease-congestion-in-the-respiratory-system
  • Article - 22/06/2008

    Nycomed sells oncology programs to 4SC

    Eight projects in the preclinical and first clinical stage will be transferred to 4SC. Nycomed decided not to further invest in oncology RD activities. 4SC develops drug candidates for inflammatory diseases cancer and infectious diseases.

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-sells-oncology-programs-to-4sc
  • Article - 19/03/2008

    Nycomed intends to move chemical production to Indian joint venture

    Nycomed and Cadila Healthcare have signed a letter agreement with the intent to amend their existing joint venture agreement to include the chemical production of active pharmaceutical ingredients (APIs) by the joint venture company Zydus Nycomed in India. Based on this agreement, Nycomed plans to transfer the current chemical production from the sites in Linz (Austria) and Singen (Germany) to the new joint venture within the next three to four…

    https://www.gesundheitsindustrie-bw.de/en/article/press-release/nycomed-intends-to-move-chemical-production-to-indian-joint-venture
  • Extend search to all portals
  • Search the Healthcare industry database
  • Search the Research institutions
Search terms
Portal
Information type
  • Type
    Event date
    From
    To
  • Type
  • Publication date
    Topics
    Topics
  • Publication date
Reset

Footer navigation

  • Healthcare industry BW
    • At a glance
    • The biotechnology sector
    • Medical technology
    • The pharmaceutical industry
    • Training & university education
    • Company foundation
    • Infrastructure
    • Clusters & Networks
  • Articles
    • Latest news
    • Selected press releases
    • Dossiers
    • Red biotechnology
    • Medical technology
    • Pharmaceutics
    • Diagnostics
    • Basic research
    • Selected publications
  • Events
  • Databases
    • Funding
    • Healthcare industry database
    • Research institutions
  • BIOPRO services
    • BIOPRO services and offers
    • Contacts
    • Information channels
  • Project pages
    • Telemedicine BW
    • MDR & IVDR
  • Portals
    • BIOPRO BW
    • Healthcare industry
    • Bioeconomy
  • To top

stay informed

Subscribe to newsletter

Social Media

  • Xing
  • Twitter
  • LinkedIn
  • Rss
  • Privacy statement
  • Legal notice
  • Sitemap
  • Contact
© 2023
Website address: https://www.gesundheitsindustrie-bw.de/en/search